Treatment of Common Iliac Artery Stenosis

Introduction to Treatment Guidelines

The American College of Radiology recommends endovascular revascularization with primary stenting combined with antiplatelet therapy as the first-line treatment for common iliac artery stenosis, with open surgery reserved for endovascular failure 1, 2, 3

For TASC A lesions, percutaneous transluminal angioplasty (PTA) alone is usually appropriate, with selective stent placement only if PTA results are suboptimal, and antiplatelet therapy should be initiated as adjunctive treatment 1, 2, 3, 4
For TASC B lesions, primary PTA or primary stenting are both usually appropriate, with antiplatelet therapy as essential adjunctive treatment, and best medical management alone is usually not appropriate 1, 2, 3, 4
For TASC C lesions, primary stenting combined with antiplatelet therapy is the first choice, with open surgery appropriate but reserved for endovascular failure, and recent data support an endovascular-first approach even for these complex lesions 1, 2, 3, 5, 6
For TASC D lesions, catheter-directed aortoiliac stent or stent-graft placement with or without femoral angioplasty combined with antiplatelet therapy is the first choice, with open surgery performed if endovascular therapy fails, and multiple societal guidelines recommend an endovascular-first approach for all TASC lesions 1, 2, 3, 6, 7

Any stenotic superficial femoral artery must be addressed at the time of iliac intervention, as untreated SFA stenosis is a strong predictor of iliac intervention failure, with only 36% 3-year primary patency 1, 2, 3, 5, 8
Covered balloon-expandable stents demonstrate superior outcomes compared to bare metal stents, particularly for TASC C and D lesions, with better binary restenosis rates, lower amputation rates, and improved clinical outcomes 2, 3

Single-agent antiplatelet therapy is mandatory for all symptomatic patients to reduce major adverse cardiovascular events and cardiovascular mortality, with the highest appropriateness rating across all TASC classifications 1, 2, 3, 4, 5, 8
High-dose statin therapy is indicated for all patients with peripheral arterial disease if tolerated, as a class IA recommendation 5, 8
A supervised exercise program should be initiated in conjunction with iliac intervention, along with risk factor modification including smoking cessation and control of hyperlipidemia, diabetes, and hypertension 1, 2, 3, 5, 8

Surgical revascularization is the best treatment for acute embolic events, with catheter-directed mechanical thrombectomy usually appropriate, and anticoagulation usually indicated except in situations such as recent surgery 1, 2, 3, 7

Endovascular and open surgical approaches have equivalent outcomes, with similar 2-year survival, limb salvage, and primary/primary-assisted patency, but endovascular revascularization is associated with increased secondary interventions and decreased hospital length of stay and postoperative complications 5, 6

Multiple independent predictors of iliac intervention failure have been identified, including hypertension, hypercholesterolemia, chronic renal insufficiency, poor tibial runoff, external iliac artery disease, female gender, smoking, gangrene, ulcer, diabetes mellitus, presence of a distal bypass, and hormone replacement therapy in female patients, with the most critical modifiable factor being addressing concomitant SFA stenosis at the time of intervention 1, 3, 5, 7